Physician profile
Gregory G Stevens
NPI 1275672420
$11,797.32
in general payments reported to CMS, 2019-2025
40 companies · $1,829 in 2025
The $1,829 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,541 · 2020: $1,798 · 2021: $1,477 · 2022: $1,561 · 2023: $1,284 · 2024: $1,309 · 2025: $1,829.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,374 · Education: $47.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,374.41 |
| Education | $47.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,230.93 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $1,450.36 | 2019-2025 | Repatha, Otezla, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,425.11 | 2019-2025 | Jardiance, Ofev |
| Astrazeneca Pharmaceuticals LP | $1,373.03 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $1,272.55 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Abbvie INC. | $543.97 | 2021-2025 | Qulipta |
| Astellas Pharma US INC | $342.94 | 2019-2023 | Veozah |
| Pfizer INC. | $307.84 | 2019-2025 | |
| Allergan, INC. | $295.41 | 2019-2020 | |
| Tris Pharma INC | $234.80 | 2023 | Quillivant, Dyanavel Xr, Quillichew Er |
| Merck Sharp & Dohme LLC | $216.13 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $215.08 | 2019-2021 | |
| Glaxosmithkline, LLC. | $214.91 | 2019-2025 | Arexvy, Trelegy Ellipta |
| Madrigal Pharmaceuticals | $170.56 | 2025 | Rezdiffra |
| Medtronic, INC. | $136.97 | 2025 | Venaseal |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Stevens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.